منابع مشابه
Survival Analysis Using Primary and Surrogate Endpoints
GAIL E. TUDOR. Survival Analysis Using Primary and Surrogate Endpoints. (Under the direction of TIMOTHY M. MORGAN) Current survival techniques do not provide a good method for handling clinical trials with a large percent of censored observations. Some methods that have been proposed to increase the power of analyses· include covariate adjustment, multivariate models, use of surrogate endpoints...
متن کاملSurrogate markers predicting overall survival for lung cancer: ELCWP recommendations.
The present systematic review was performed under the auspices of the European Lung Cancer Working Party (ELCWP) in order to determine the role of early intermediate criteria (surrogate markers), instead of survival, in determining treatment efficacy in patients with lung cancer. Initially, the level of evidence for the use of overall survival to evaluate treatment efficacy was reviewed. Nine q...
متن کاملProgression-free survival as a potential surrogate for overall survival in metastatic breast cancer
BACKGROUND Progression-free survival (PFS) and time to progression (TTP) are frequently used to establish the clinical efficacy of anti-cancer drugs. However, the surrogacy of PFS/TTP for overall survival (OS) remains a matter of uncertainty in metastatic breast cancer (mBC). This study assessed the relationship between PFS/TTP and OS in mBC using a trial-based approach. METHODS WE CONDUCTED ...
متن کاملCan disease-free survival be a surrogate for overall survival for drug approvals?
The gold standard test for clinical benefit of oncology drugs is improvement in overall survival. The U.S. Food and Drug Administration allows drugs to be approved if they improve patient survival or if there is evidence that reliably predicts clinical benefit, such as an established surrogate. In a recent analysis of the 57 oncology drug applications approved in the last 13 years through the r...
متن کاملInterpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
Alexander et al recently introduced a different interpretation involving our paper, in which we systematically evaluated glioblastoma clinical trials published from 1991 to the present and demonstrated that progression-free survival (PFS) may be an appropriate surrogate endpoint for overall survival (OS). Although the authors did not raise any methodological and clinical questions directly to u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JACC: Cardiovascular Imaging
سال: 2018
ISSN: 1936-878X
DOI: 10.1016/j.jcmg.2017.11.003